First Tracks Biotherapeutics Inc (TRAX) Stock Price, Quote & News

Company Profile

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifical...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 362 6295

Website: www.firsttracksbio.com

Address:

10770 Wateridge Circle, Suite 210, San Diego, United States

gracehh Jul. 30 at 9:36 PM

$THC $TRAX sui11

0 · Reply

StockBraker Jul. 30 at 2:03 PM

$TRAX Got 1,000 shares you would like to sell by mid-October for $60? Sell a covered call and collect between $2,000-6,500 today in premiums and $60,000 on the expiration date if the price gets and stays above $60.

0 · Reply

StockBraker Jul. 30 at 1:58 PM

$TRAX

0 · Reply

Jt11111 Jul. 29 at 6:22 PM

$TRAX $ANAB solid Jemperil sales from gsk —$320MM keep ANAB royalty on track and this is a steal at $50. 1. H1 2026 Actual Sales (First Half) Q1 2026: £232 million ($313 million USD) Q2 2026: £248 million ($320 million USD) Total H1 2026: £480 million GBP (~$620 million USD)

1 · Reply

StockBraker Jul. 27 at 10:59 PM

$TRAX I need to keep an eye out for more of his trashcan posts.

0 · Reply

STACKD0E Jul. 27 at 5:07 PM

$JBS $GENI $TRAX $RNG ✨

0 · Reply

notreload_ai Jul. 27 at 4:25 PM

H.C. Wainwright says $FBRX acquisition is positive for $TRAX because Forte’s drug competes with TRAX’s ANB033. The firm believes this could increase interest in First Tracks if clinical results are successful and keeps a Buy rating while reviewing its valuation.

0 · Reply

MikeyNJ Jul. 27 at 2:29 PM

$TRAX Wedbush raises price target to $60.

0 · Reply

Nickman18 Jul. 27 at 2:23 PM

$ANAB $TRAX I've owned since 2019 with a price average of 20.66 just wanted to brag quickly

1 · Reply

topstockalerts Jul. 27 at 1:27 PM

Pre Market Top Gainers PT2 $ENTX $FBRX $JZXN $TRAX $GOSS

0 · Reply

First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush

ARGX FBRX TEVA

2026-07-28T10:15:32.000Z - 6 days ago

First Tracks Biotherapeutics price target raised to $55 from $30 at Wells Fargo

FBRX

2026-07-21T10:20:10.000Z - 13 days ago

First Tracks Biotherapeutics price target raised to $48 from $40 at Barclays

2026-07-10T10:05:09.000Z - 24 days ago

First Tracks Biotherapeutics price target raised to $44 from $30 at H.C. Wainwright

FBRX

2026-06-08T09:00:08.000Z - 2 months ago

First Tracks Biotherapeutics initiated with an Overweight at Wells Fargo

Jun 3, 2026, 12:15 PM EDT - 2 months ago

First Tracks Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 21, 2026, 4:15 PM EDT - 2 months ago

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

May 14, 2026, 4:15 PM EDT - 2 months ago

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 7:00 AM EDT - 2 months ago

First Tracks Biotherapeutics Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 2 months ago

First Tracks Biotherapeutics Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 2 months ago

First Tracks Biotherapeutics Slides: Corporate presentation

2026-05-08T22:52:09.000Z - 3 months ago

First Tracks Biotherapeutics files to sell 10.5M shares of common for holders

May 8, 2026, 8:00 AM EDT - 3 months ago

First Tracks Biotherapeutics Registration statement: Registration filing

2026-05-04T08:40:30.000Z - 3 months ago

First Tracks Biotherapeutics initiated with an Overweight at Piper Sandler

2026-04-28T10:10:15.000Z - 3 months ago

First Tracks Biotherapeutics initiated with a Buy at H.C. Wainwright

2026-04-24T11:36:50.000Z - 3 months ago

First Tracks Biotherapeutics initiated with an Outperform at Leerink

ANAB

2026-04-23T12:11:58.000Z - 3 months ago

First Tracks Biotherapeutics initiated with an Overweight at Barclays

2026-04-23T12:11:27.000Z - 3 months ago

First Tracks Biotherapeutics initiated with an Overweight at JPMorgan

Apr 20, 2026, 9:15 AM EDT - 3 months ago

First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases

gracehh Jul. 30 at 9:36 PM

$THC $TRAX sui11

0 · Reply

StockBraker Jul. 30 at 2:03 PM

0 · Reply

StockBraker Jul. 30 at 1:58 PM

$TRAX

0 · Reply

Jt11111 Jul. 29 at 6:22 PM

1 · Reply

StockBraker Jul. 27 at 10:59 PM

$TRAX I need to keep an eye out for more of his trashcan posts.

0 · Reply

STACKD0E Jul. 27 at 5:07 PM

$JBS $GENI $TRAX $RNG ✨

0 · Reply

notreload_ai Jul. 27 at 4:25 PM

0 · Reply

MikeyNJ Jul. 27 at 2:29 PM

$TRAX Wedbush raises price target to $60.

0 · Reply

Nickman18 Jul. 27 at 2:23 PM

$ANAB $TRAX I've owned since 2019 with a price average of 20.66 just wanted to brag quickly

1 · Reply

topstockalerts Jul. 27 at 1:27 PM

Pre Market Top Gainers PT2 $ENTX $FBRX $JZXN $TRAX $GOSS

0 · Reply

Daytradingdude Jul. 27 at 12:22 PM

$DFNS $FBRX $LGHL $MTNB $TRAX

0 · Reply

topstockalerts Jul. 27 at 12:22 PM

Pre Market Top Gainers $LGHL $MTNB $DFNS $FBRX $TRAX

0 · Reply

StockBraker Jul. 27 at 11:43 AM

$TRAX Thanks Argenx. Waiting before selling any more FirstTracks

0 · Reply

StockBraker Jul. 27 at 11:24 AM

$TRAX Forte Biosciences and AnaptysBio are connected as the two primary competitors developing therapies in the CD122 (IL-2/IL-15 receptor beta) space for autoimmune and inflammatory diseases. The connection became highly relevant following news that pharmaceutical giant Argenx agreed to acquire Forte Biosciences for $2.2 billion. This acquisition directly impacts the competitive landscape for AnaptysBio's spin-off assets. https://finance.yahoo.com/healthcare/articles/argenx-agrees-2-2-billion-104613226.html

0 · Reply

topstockalerts Jul. 27 at 11:20 AM

Pre Market Top Gainers PT2 $TRAX $SXTC $VEEE $AIMD $TAOX

0 · Reply

StockBraker Jul. 27 at 11:14 AM

$TRAX Why are all the Stocktwits prices wrong this morning?

0 · Reply

DekmarTrades Jul. 27 at 11:08 AM

I see no news on $TRAX, but still the stock is up 40% and looking for new highs! Continued momentum from earlier July gains tied to positive read-through from competitor data (Forte Biosciences / FBRX Phase 1b vitiligo results validating the broader CD122 pathway).

0 · Reply

Koko__deep Jul. 27 at 10:58 AM

$TRAX 🫨

0 · Reply

StockBraker Jul. 23 at 12:31 PM

$TRAX Almost there 👇🏼- Just need to verify the volume PM

1 · Reply

StockBraker Jul. 22 at 3:54 PM

$TRAX Looking for $47-51 in the short term.

1 · Reply

WallStreetWatcher1 Jul. 20 at 8:09 PM

Five stocks with market capitalizations under $10 billion are on my watchlist. Not because they've already made the biggest move... But because I believe they still have the potential to create outsized returns over the coming years. This month's focus: 1. $FBRX +129% 2. $CRNX +117% 3. $TRAX +96% 4. $PHOE +78% 5. $ALIT +58% The biggest winners are rarely obvious when they're still small. That's why I spend more time building my watchlist than chasing headlines. Next alert is coming soon. If you're not following with notifications on, you're likely seeing the move after it already happened.

0 · Reply

QuietLattice Jul. 18 at 5:05 AM

$TRAX green close Fri, bear day tag. mid-day ~17x vol dump off the ~40 poke. melt-up still getting sold into

0 · Reply

Market Cap	1.54B
Revenue (ttm)	0.00
Net Income (ttm)	-163.71M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	869,600
Avg Vol	785,734
Day's Range	N/A - N/A
Shares Out	34.89M
Stochastic %K	70%
Beta	N/A
Analysts	Strong Sell
Price Target	$50.75